Norway's Zelluna ASA reports Q2 loss

Zelluna ASA

20/08/2026 06:14

Overview
Norway cell therapy developer reported Q2 operating loss of NOK 19.7 mln
First patient dosed in ZIMA-101 Phase 1 study; favorable initial safety data reported
Company raised NOK 58.2 mln in private placement and retail offering during Q2

Outlook
Zelluna says patient recruitment for ZIMA-101 Phase 1 trial is ongoing at two sites
Company expects cash position to fund operations into Q3 2027
Zelluna continues to strengthen manufacturing capabilities to support future development of TCR-NK platform

Result Drivers
CLINICAL TRIAL INITIATION - First patient dosed in ZIMA-101 Phase 1 study; favorable initial safety observations supported continued enrolment
ADDITIONAL CLINICAL SITE - Activation of The Royal Marsden as second clinical site to strengthen patient recruitment for ZIMA-101
FUNDING SUPPORT - NOK 58.2 mln raised in private placement and retail offering, and NOK 16 mln grant awarded to support clinical trial and operations

Company press release: ID:nGNE6XvW2l

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Operating Expenses
 
NOK 19.90 mln
 

Reuters Recommended Reads
Aug 19 - Sweden's Cantargia narrows H1 loss, raises SEK 132 mln
Aug 17 - Cancer immunotherapy developer CEL-SCI's Q3 net loss unchanged
Aug 18 - Germany's Immatics Q2 revenue rises but misses estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)